Liminal BioSciences To Sell Rare Pediatric Disease Priority Review Voucher For $105 Mln

Liminal BioSciences Inc. (LMNL) said that, its subsidiary Prometic Biotherapeutics Inc. or "PBT", agreed to sell its Rare Pediatric Disease Priority Review Voucher or "PRV" for US$105 million.

The PRV was granted by the U.S. Food and Drug Administration with the approval of Ryplazim (plasminogen, human-tvmh), for treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia).

Under the terms of the previously announced Share Purchase Agreement entered into with Kedrion S.p.A dated June 22, 2021; Liminal Biosciences is entitled to retain an amount equal to 70% of the net sales proceeds of the sale of the PRV.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Delta Air Lines said it sees weather-related flight cancelations as AT&T and Verizon readies for 5G roll out in and around the vicinity of major U.S. airports. Most of the other airlines also confirmed the same as the implementation of the new C-Band 5G service is expected to interfere with the working of onboard aircraft instruments. Financial services firm Morgan Stanley (MS) reported Wednesday a profit for the fourth quarter that increased 10 percent from last year, reflecting 7 percent revenue growth amidst strength in Wealth Management and Investment Management business segments. Bank of America Corp. (BAC) reported Thursday that net income applicable to common shareholders for the fourth quarter grew 30 percent to $6.77 billion from last year's $5.21 billion, with earnings per share increasing to $0.82 from $0.59 in the prior year, reflecting strong operating leverage as revenues...
Follow RTT